Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial

• Published in: Frontiers in immunology Vol. 15; p. 1425906
• Main Authors: Ghanei, Mostafa, Ghalebaghi, Babak, Sami, Ramin, Torabizadeh, Mehdi, Mirsadraee, Majid, Amra, Babak, Tavakol, Marzieh, Raji, Hanieh, Fallahpour, Morteza, Kiani, Arda, Abedini, Atefeh, Jabbari Azad, Farahzad, Mahdaviani, Seyed Alireza, Attaran, Davood, Samet, Mohammad, Tavana, Sasan, Haddadzadeh Shoushtari, Maryam, Nazari, Javad, AghaeiMeybodi, FatemehAlsadat, Fazlollahi, Mohammad Reza, Ghasemi, Ramin, Sabzvari, Araz, Kafi, Hamidreza, Idani, Esmaeil
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.07.2024
• Subjects: Adult; allergic; Anti-Asthmatic Agents - adverse effects; Anti-Asthmatic Agents - therapeutic use; asthma; Asthma - drug therapy; biosimilar; Biosimilar Pharmaceuticals - adverse effects; Biosimilar Pharmaceuticals - therapeutic use; Double-Blind Method; Female; Humans; IgE; Immunoglobulin E - blood; Immunoglobulin E - immunology; Immunology; Male; Middle Aged; omalizumab; Omalizumab - adverse effects; Omalizumab - therapeutic use; Severity of Illness Index; Therapeutic Equivalency; Treatment Outcome; Young Adult; allergic; asthma; omalizumab; IgE; biosimilar
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1425906

Allergic asthma has a considerable burden on the quality of life. A significant portion of moderate-to-severe allergic asthma patients need omalizumab, an anti-immunoglobulin-E monoclonal antibody, as an add-on therapy. In this phase III clinical trial P043 (Zerafil , CinnaGen, Iran) efficacy, safety, and immunogenicity were compared with Xolair (the originator omalizumab). The primary outcome was the rate of protocol-defined asthma exacerbations. Exacerbation rates, Asthma Control Test (ACT) results, spirometry measurements, immunogenicity, and safety were evaluated. Each subject received either medication with a dose ranging from 150 to 375 mg based on pre-treatment serum total IgE level (IU/mL) and body weight (kg) every two or four weeks for a duration of 28 weeks. Exacerbation rates were 0.150 (CI: 0.079-0.220) in the P043 group, and 0.190 (CI: 0.110-0.270) in the omalizumab group (per-protocol). The least squares mean differences of predicted Forced Expiratory Volume in the First second (FEV ) were -2.51% (CI: -7.17-2.15, P=0.29) and -3.87% (CI: -8.79-1.04, P=0.12), pre- and post-bronchodilator use. The mean ± SD of ACT scores at the screening and the last visit were 10.62 ± 2.93 and 20.93 ± 4.26 in P043 and 11.09 ± 2.75 and 20.46 ± 5.11 in the omalizumab group. A total of 288 adverse events were reported for the 256 enrolled participants. Among all, "dyspnea" and "headache" were the most reported ones. The overall incidence of adverse events (P=0.62) and serious adverse events (P=0.07) had no significant differences between the two groups. None of the samples were positive for anti-drug antibodies. P043 was equivalent to omalizumab in the management of asthma in reduction of exacerbations. There was no significant difference in other efficacy and safety parameters. www.clinicaltrials.gov (NCT05813470) and www.IRCT.ir (IRCT20150303021315N20).